Interesting that under the "Acquisitions" on page

Interesting that under the "Acquisitions" on page 12, here is everything it says under Olaregen:


"On November 24, 2019, the Company amended the Stock Purchase Agreement with Olaregen. The Company was obligated to pay in full $11,600,000 to Olaregen by November 30, 2019, in connection with the purchase of Olaregen capital stock. Effective November 24, 2019, the deadline has been extended to January 31, 2020. The Company is negotiating the terms of a new extension and there has been no demand for payment at this time."

So combined with Paul's quote, which I found on page 20:


"On February 14, 2020, Olaregen exchanged all of its outstanding shares for 5,950,000 shares of Generex common stock and 2,765,000 shares of NGIO in. After this transaction, Generex owns 100% of the outstanding shares of Olaregen.",

...can we safely assume the matter is completely closed, or could there still be a debt outstanding?

If that closes the Olaregen deal for in total, that is a milestone. If we still somehow owe millions in addition to the stock...